Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AETHLON MEDICAL INC (AEMD)

Aethlon Medical agrees to merge with North Immunology; Aethlon holders to own 4.75%

Mixed Impact 5 of 5 m&a Written later

Aethlon Medical and private biotech North Immunology signed a merger agreement in which North Immunology becomes a wholly owned subsidiary of Aethlon and the combined company is renamed North Immunology, Inc. Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, while Aethlon stockholders also receive contingent value rights tied to proceeds, if any, from a sale or other monetization of its legacy Hemopurifier business.

Key points

  • Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company; North Immunology holders, including Private Placement investors, about 95.25%
  • Concurrent private placement expected to provide about $180 million, including about $34 million from converted notes; closing requires at least $175 million in proceeds
  • Expected to close in the first quarter of 2027; either party may terminate if not closed by June 17, 2027; termination fees are $300,000 (Aethlon) and $2,000,000 (North Immunology) in specified cases
  • Combined company expected to trade on Nasdaq Capital Market under ticker NRTX and be led by North Immunology's CEO

The filing

CompanyAETHLON MEDICAL INC (AEMD)
Form8-K, current report
Filed with the SECSep 17, 2026, 8:03 AM ET
Accession number0001683168-26-007206

Items reported: 1.01 Material Definitive Agreement5.01 Change in Control7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.